image description

Tag: Lucin

LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020

30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More

Lupus Therapeutics Collaborating with PPD to Accelerate Lupus Clinical Research

September 3, 2020 PPD, Inc. issued a press release  today announcing its collaboration with the Lupus Research Alliance affiliate Lupus Therapeutics to optimize lupus clinical research among its pharmaceutical and biotech clients. As a contract research organization, PPD helps its clients design and implement clinical trials. PPD expects to gain from Lupus Therapeutics’ deep clinical […] Read More

PALS Clinical Trial Program Opens at Five Universities

August 8, 2019 In five pilot cities, people with lupus who are thinking about taking part in a clinical trial can now join LRA’s Patient Advocates for Lupus Studies (PALS) program created by our affiliate Lupus Therapeutics. The program will pair adults with lupus interested in learning about clinical trials with a peer or “PAL” who […] Read More

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and clinical research affiliate, Lupus Therapeutics, broadened a collaboration with Bristol-Myers Squibb (BMS) to study the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN) – kidney damage affecting about 50 percent of people with lupus. This expands the existing collaboration in systemic lupus erythematosus (SLE). […] Read More

Remember During Men’s Health Month that Men Get Lupus Too

June 20, 2019 Michael Lauria knows only too well that lupus is not just a woman’s disease – he was diagnosed in the prime of his life – when he was just 32 years old. And he is counting on the Lupus Research Alliance to find the answers that will change his life. Young, fit, […] Read More

Stelara® Effective Over One Year and Reduces Severe Flares

Results of two analyses from a Phase 2 study of Stelara® (ustekinumab) in lupus showed the drug’s effectiveness over one year. Both highlight the benefit of ustekinumab on disease activity and the rate of severe flares. Ustekinumab reduced the rate of severe flares four times as much as placebo by week 24. The rate of […] Read More

LRA Researchers Reveal New Drug Targets at Leading Immunology Conference

May 22, 2019 Data presented by several Lupus Research Alliance-funded scientists at the recent American Association of Immunologists Annual Meeting suggests many  avenues for new lupus treatments. Some scientists presented data posing new targets for drug development, while others have discovered cells that suppress the immune response and could be harnessed as treatments. Reining in […] Read More

Celebrate Clinical Trials Day May 20!

May 20, 2019 It’s Clinical Trials Day when the Lupus Research Alliance recognizes all the people we support who advance clinical research – scientists who identify and develop potential ways to diagnose, monitor and treat lupus,  researchers who design and conduct the studies to test these methods, and the volunteers who take part in the […] Read More